Defence Therapeutics targets ADC licensing deals to expand Accum adoption

• Defence Therapeutics set a 12-month plan centered on expanding Accum-enabled oncology programs through partnerships and internal development.
• Strategy prioritizes Accum-enhanced antibody-drug conjugates, targeting revenue-generating collaborations and licensing to drive broader adoption.
• Radiotherapeutics program to advance toward clinical development, focusing on data generation to select the most promising Accum-enabled assets.
• AccuTOX path to be decided, weighing out-licensing, co-development, or selective restart of clinical work, with melanoma the lead indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Defence Therapeutics Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609080315NEWSFILECNPR____20260908_313184_1) on September 08, 2026, and is solely responsible for the information contained therein.